Regulation of angiogenesis in malignancies associated with Epstein-Barr virus and Kaposi's sarcoma-associated herpes virus

Future Microbiology

Volumn 4, Issue 7, 2009, Pages 903-917

  Sakakibara, Shuhei ^a   Tosato, Giovanna ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; EBV; Gastric carcinoma; Kaposi's sarcoma; KSHV; NPC

Indexed keywords

CYCLINE; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K 13; NOTCH RECEPTOR; PROTEIN LMP1; PROTEIN LMP2; PROTEIN LMP2A; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS DNA; VIRUS PROTEIN;

CELL CYCLE REGULATION; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; GENE ACTIVATION; GENE FUNCTION; GENETIC REGULATION; HUMAN; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; LIFE CYCLE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; STOMACH CARCINOMA; TUMOR VASCULARIZATION; VIRAL GENETICS; VIRUS CARCINOGENESIS; VIRUS GENE;

EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HUMANS; MODELS, BIOLOGICAL; NASOPHARYNGEAL NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SARCOMA, KAPOSI; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 8;

EID: 70349206304     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.09.49     Document Type: Review

References (141)

1. Ferrara N, Kerbel RS: Angiogenesis as a therapeutic target. Nature 438(7070), 967-974 (2005).
2. Tzankov A, Heiss S, Ebner S et al.: Angiogenesis in nodal B cell lymphomas: a high throughput study. J. Clin. Pathol. 60(5), 476-482 (2007).
3. Nakayama T, Yao L, Tosato G: Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. J. Clin. Invest. 114(9), 1317-1325 (2004).
4. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100(1), 57-70 (2000).
5. Algire G: Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J. Natl Cancer Inst. 6, 73-85 (1945).
6. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat. Med. 9(6), 669-676 (2003).
7. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L: VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 7(5) 359-371 (2006).
8. Folkman J: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182-1186 (1971).
9. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1(1), 27-31 (1995).
10. Crawford Y, Ferrara N: VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res. 335(1), 261-269 (2009).
11. Shojaei F, Ferrara N: Antiangiogenesis to treat cancer and intraocular neovascular disorders. Lab. Invest. 87(3), 227-230 (2007).
12. Carmeliet P: Angiogenesis in health and disease. Nat. Med. 9(6), 653-660 (2003).
13. Hendrix MJ, Seftor EA, Hess AR, Seftor RE: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer 3(6), 411-421 (2003).
14. Jain RK: Molecular regulation of vessel maturation. Nat. Med. 9(6), 685-693 (2003).
15. Bugert JJ, Darai G: Poxvirus homologues of cellular genes. Virus Genes 21(1-2), 111-133 (2000).
16. Lee LF, Wu P, Sui D et al.: The complete unique long sequence and the overall genomic organization of the GA strain of Marek's disease virus. Proc. Natl Acad. Sci. USA 97(11), 6091-6096 (2000).
17. Meyer M, Clauss M, Lepple-Wienhues A et al.: A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 18(2), 363-374 (1999).
18. Wolf H, Haus M, Wilmes E: Persistence of Epstein-Barr virus in the parotid gland. J. Virol. 51(3), 795-798 (1984).
19. Young LS, Rickinson AB: Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4(10), 757-768 (2004).
20. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA: EBV persistence in memory B cells in vivo. Immunity 9(3), 395-404 (1998).
21. Rickinson AB, Moss DJ: Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15, 405-431 (1997).
22. Laichalk LL, Thorley-Lawson DA: Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J. Virol. 79(2), 1296-1307 (2005).
23. + B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am. J. Surg. Pathol. 27(1) 16-26 (2003).
24. Ohshima K, Kimura H, Yoshino T et al.: Proposed categorization of pathological states of EBV-assoqated T/natura1 killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol. Int. 58(4), 209-217 (2008).
25. Klein G, Giovanella BC, Lindahl T, Fialkow PJ, Singh S, Stehlin JS: Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc. Natl Acad. Sci. USA 71(12), 4737-4741 (1974).
26. Shanmugaratnam K, Chan SH, de-The G et al.: Histopathology of nasopharyngeal carcinoma: correlations with epidemiology, survival-rates and other biological characteristics. Cancer 44(3), 1029-1644 (1979).
27. Hengge UR, Brockmeyer NH, Baumann M, Reimann G, Goos M: Liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Lancet 342(8869), 497 (1993).
28. Yates JL, Warren N, Sugden B: Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313(6005), 812-815 (1985).
29. Yin Y, Manoury B, Fahraeus R: Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 301(5638), 1371-1374 (2003).
30. Kang MS, Hung SC, Kieff E: Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth. Proc. Natl Acad. Sci. USA 98(26), 15233-15238 (2001).
31. Gruhne B, Sompallae R, Marescotti D, Kamranvar SA, Gastaldello S, Masucci MG: The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species. Proc. Natl Acad. Sci. USA 106(7), 2313-2318 (2009).
32. Ning S, Campos AD, Darnay BG, Bentz GL, Pagano JS: TRAF6 and the three C-terminal lysine sites on IRF7 are required for its ubiquitination-mediated activation by the tumor necrosis factor receptor family member latent membrane protein 1. Mol. Cell. Biol. 28(20), 6536-6546 (2008).
33. Song YJ, Izumi KM, Shinners NP, Gewurz BE, Kieff E: IRF7 activation by Epstein-Barr virus latent membrane protein I requires localization at activation sites and TRAF6, but not TRAF2 or TRAF3. Proc. Natl Acad. Sci. USA 105(47), 18448-18453 (2008).
34. Soni V, Cahir-McFarland E, Kieff E: LMP1 trafficking activates growth and survival pathways. Adv. Exp. Med. Biol. 597, 173-187 (2007).
35. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R: Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9(3), 405-411 (1998).
36. Scholle F, Bendt-KM, Raab-Traub N: Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J. Virol. 74(22), 10681-10689 (2000).
37. Morrison JA, Klingelhurz AJ, Raab-Traub N: Epstein-Barr virus latent membrane protein 2A activates β-catenin signaling in epithelial cells. J. Virol. 77(22), 12276-12284 (2003).
38. Nanbo A, Inoue K, Adachi-Takasawa K, Takada K: Epstein-Barr virus RNA confers resistance to interferon-α-induced apoptosis in Burkitt's lymphoma. EMBO J. 21(5), 954-965 (2002).
39. Sall A, Caserta S, Jolicoeur P, Franqueville L, de Turenne-Tessier M, Ooka T: Mitogenic activity of Epstein-Barr virus-encoded BARF1 protein. Oncogene 23(28), 4938-4944 (2004).
40. Strockbine LD, Cohen JI, Farrah T et al.: The Epstein-Barr virus BARF1 gene encodes a novel, soluble colony-stimulating factor-1 receptor. J. Virol. 72(5), 4015-4021 (1998).
41. Kusano S, Raab-Traub N: An Epstein-Barr virus protein interacts with Notch. J. Virol. 75(1), 384-395 (2001).
42. Lo AK, To KF, Lo KW et al.: Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc. Natl Acad. Sci. USA 104(41), 16164-16169 (2007).
43. Ballestas ME, Chatis PA, Kaye KM: Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 284(5414), 641-644 (1999).
44. Fujimuro M, Wu FY, ApRhys C et al.: A novel viral mechanism for dysregulation of β-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat. Med. 9(3), 300-306 (2003).
45. Sakakibara S, Ueda K, Nishimura K et al.: Accumulation of heterochromatin components on the terminal repeat sequence of Kaposi's sarcoma-associated herpesvirus mediated by the latency-associated nuclear antigen. J. Virol. 78(14), 7299-7310 (2004).
46. Kwun HJ, da Silva SR, Shah IM, Blake N, Moore PS, Chang Y: Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mimics Epstein-Barr virus EBNA1 immune evasion through central repeat domain effects on protein processing. J. Virol. 81(15), 8225-8235 (2007).
47. Swanton C, Mann DJ, Fleckenstein B, Neipel F, Peters G, Jones N: Hespes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 390(6656), 184-187 (1997).
48. Field N, Low W, Daniels M et al.: KSHV vFLIP binds to IKK-γ to activate IKK. J. Cell Sci. 116(Pt 18), 3721-3728 (2003).
49. McCormick C, Ganem D: The kaposin B protein of KSHV activates tht p38/ MK2 pathway and stabilizes cytokine mRNAs. Science 307(5710), 739-741 (2005).
50. Ziegelbauer JM, Sullivan CS, Ganem D: Tandem array-based expressioa screens identify host mRNA targets of virus-encoded microRNAs. Nat. Genet. 41(1), 130-134 (2009).
51. Gottwein E, Mukherjee N, Sachse C et al.: A viral microRNA functions as an orthologue of cellular miR-155. Nature 450(7172), 1096-1099 (2007).
52. Murono S, Inoue H, Tanabe T et al.: Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc. Natl Acad. Sci. USA 98(12), 6905-6910 (2001).
53. Guang-Wu H, Sunagawa M, Jie-En L et al.: The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma. Laryngoscope 110(12), 2066-2069 (2000).
54. Qian CN, Zhang CQ, Guo X et al.: Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma. Cancer 88(2), 255-261 (2000).
55. Wakisaka N, Wen QH, Yoshizaki T et al.: Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma Laryngoscope 109(5), 810-814 (1999).
56. Qian CN, Min HQ, Lin HL et al.: Anti-tumor effect of angiogenesis inhibitor TNP-470 on the human nasopharyngeal carcinoma cell line NPC/ HK1. Oncology 57(1), 36-41 (1999).
57. Parsonnet J, Friedman GD, Vandersteen DP et al.: Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 325(16), 1127-1131 (1991).
58. Sakamoto H, Yoshimura K, Saeki N et al.: Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat. Genet. 40(6), 730-740 (2008).
59. Shibata D, Tokunaga M, Uemura Y, Sato E, Tanaka S, Weiss LM: Association of Epstein-Barr virus with undifferentiated gastric carcinomas with intense lymphoid infiltration. Lymphoepithelioma-like carcinoma. Am. J. Pathol. 139(3), 469-474 (1991).
60. Oshima H, Oshima M, Inaba K, Taketo MM: Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J 23(7), 1669-1678 (2004).
61. Seno H, Oshima M, Ishikawa TO et al.: Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(δ716) mouse intestinal polyps. Cancer Res. 62(2), 506-511 (2002).
62. Imai S, Koizumi S, Sugiura M et al.: Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc. Natl Acad. Sci. USA 91(19), 9131-9135 (1994).
63. Salmon JS, Lockhart AC, Berlin J: Anti-angiogenic treatment of gastrointestinal malignancies. Cancer Invest. 23(8), 712-726 (2005).
64. Lohela M, Helotera H, Haiko P, Dumont DJ, Alitalo K: Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues. Am. J. Pathol. 173(6), 1891-1901 (2008).
65. Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, Detmar M: VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 109(3), 1010-1017 (2007).
66. Karpanen T, Alitalo K: Molecular biology and pathology of lymphangiogenesis. Annu. Rev. Pathol. 3, 367-397 (2008).
67. Gao P, Zhou GY, Zhang QH et al.: Lymphangiogenesis in gastric carcinoma correlates with prognosis. J. Pathol. 218(2), 192-200 (2009).
68. Parravicini C, Chandran B, Corbellino M et al.: Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am. J. Pathol. 156(3), 743-749 (2000).
69. Whitby D, Howard MR, Tenant-Flowers M et al.: Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 346(8978), 799-802 (1995).
70. Della Bella S, Taddeo A, Calabro ML et al.: Peripheral blood endothelial progenitors as potential reservoirs of Kaposi's sarcoma-associated herpesvirus. PLoS ONE 3(1), e1520 (2008).
71. Yao L, Salvucci O, Cardones AR et al.: Selective expression of stromal-derived factor-1 in the capillary vascular endothelium plays a role in Kaposi sarcoma pathogenesis. Blood 102(12), 3900-3905 (2003).
72. Bourboulia D, Aldam D, Lagos D et al.: Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS 18(3), 485-493 (2004).
73. Yarchoan R, Pluda JM, Wyvill KM et al.: Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity. Crit. Rev. Immunol. 27(5), 401-414 (2007).
74. Ahsan N, Kanda T, Nagashima K, Takada K: Epstein-Barr virus transforming protein LMP1 plays a critical role in virus production. J. Virol. 79(7), 4415-4424 (2005).
75. Mosialos G, Birkenbuch M, Yalamanchili R, VanArsdale T, Ware C, Kieff E: The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80(3), 389-399 (1995).
76. Paine E, Scheinman RI, Baldwin AS Jr, Raab-Traub N: Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-κB/Rel family proteins. J. Virol. 69(7), 4572-4576 (1995).
77. Schneider F, Neugebauer J, Griese J et al.: The viral oncoprotein LMP1 exploits TRADD for signaling by masking its apoptotic activity. PLoS Biol. 6(1), e8 (2008).
78. Chen H, Hutt-Fletcher L, Cao L, Hayward SD: A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus. J. Virol. 77(7), 4139-4148 (2003).
79. Gires O, Kohlhuber F, Kilger E et al.: Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J. 18(11), 3064-3073 (1999).
80. Mainou BA, Everly DN Jr, Raab-Traub N: Unique signaling properties of CTAR1 in LMP1-mecliated transformation. J. Virol. 81(18), 9680-9692 (2007).
81. Vaysberg M, Hatton O, Lambert SL et al.: Tumor-derived variants of Epstein-Barr virus latent membrane protein 1 induce sustained Erk activation and c-Fos. J. Biol. Chem. 283(52), 36573-36585 (2008).
82. Thornburg NJ, Kulwichit W, Edwards RH, Shair KH, Bendt KM, Raab-Traub N: LMP1 signaling and activation of NF-κB in LMP1 transgenic mice. Oncogene 25(2), 288-297 (2006).
83. Kondo S, Wakisaka N, Schell MJ et al.: Epstein-Barr virus latent membrane protein 1 induces the matrix metalloproteinase-1 promoter via an Ets binding site formed by a single nucleotide polymorphism: enhanced susceptibility to nasopharyngeal carcinoma. Int. J. Cancer 115(3), 368-376 (2005).
84. Yoshizaki T, Horikawa T, Qing-Chun R et al.: Induction of interlekin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin. Cancer Res. 7(7), 1946-1951 (2001).
85. Wakisaka N, Murono S, Yoshizaki T, Furukawa M, Pagano JS: Epstein Barr virus latent membrane protein 1 induces and causes release of fibroblast growth factor-2. Cancer Res. 62(21), 6337-6344 (2002).
86. Kung CP, Raab-Traub N: Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor through effects on Bcl-3 and STAT3. J. Virol. 82(11), 5486-5493 (2008).
87. Stevenson D, Charalambous C, Wilson JB: Epstein-Barr virus latent membrane protein 1 (CAO) up-regulates VEGF and TGF α concomitant with hyperlasia, with subsequent up-regulation of p16 and MMP9. Cancer Res. 65(19), 8826-8835 (2005).
88. Sample J, Liebowitz D, Kieff E: Two related Epstein-Barr virus membrane proteins are encoded by separate genes. J. Virol. 63(2), 933-937 (1989).
89. Miller CL, Lee JH, Kieff E, Longnecker R: An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc. Natl Acad. Sci. USA 91(2), 772-776 (1994).
90. Miller CL, Burkhardt AL, Lee JH et al.: Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 2(2), 155-166 (1995).
91. Moody CA, Scott RS, Su T, Sixbey JW: Length of Epstein-Barr virus termini as a determinant of epithelial cell clonal emergence. J. Virol. 77(15), 8555-8561 (2003).
92. Longnecker R, Miller CL, Miao XQ, Marchini A, Kieff E: The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential. J. Virol. 66(11), 6461-6469 (1992).
93. Morin PJ: β-catenin signaling and cancer. Bioessays 21(12), 1021-1030 (1999).
94. Easwaran V, Lee SH, Inge L et al.: β-catenin regulates vascular endothelial growth-factor expression in colon cancer. Cancer Res. 63(12), 3145-3153 (2003).
95. Portis T, Longnecker R: Epstein-Barr virus LMP2A interferes with global transcription factor regulation when expressed during. B-lymphocyte development. J. Virol. 77(1), 105-114 (2003).
96. Anderson LJ, Longnecker R: An auto-regulatory loop for EBV LMP2A involves activation of Notch. Virology 371(2), 257-266 (2008).
97. Iso T, Hamamori Y, Kedes L: Notch signaling in vascular development. Arterioscler. Thromb. Vasc. Biol. 23(4), 543-553 (2003).
98. Krebs LT, Xue Y, Norton CR et al.: Notch signaling is essential for vascular morphogenesis in mice. Genes Dev. 14(11), 1343-1352 (2000).
99. Shawber CJ, Das I, Francisco E, Kitajewski J: Notch signaling in primary endothelial cells. Ann. NY Acad. Sci. 995, 162-170 (2003).
100. Uyttendaele H, Ho J, Rossant J, Kitajewski J: Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium. Proc. Natl Acad. Sci. USA 98(10), 5643-5648 (2001).
101. Noguera-Troise I, Daly C, Papadopoulos NJ et al.: Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444(7122), 1032-1037 (2006).
102. Ridgway J, Zhang G, Wu Y et al.: Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444(7122), 1083-1087 (2006).
103. Zavadil J, Cermak L, Soto-Nieves N, Bottinger EP: Integration of TGF-β/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J. 23(5), 1155-1165 (2004).
104. Miyamoto Y, Maitra A, Ghosh B et al.: Notch mediates TGF α-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3(6), 565-576 (2003).
105. Crisan M, Yap S, Casteilla L et al.: A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3(3), 301-313 (2008).
106. Hu S, Vincenz C, Buller M, Dixit VM: A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis. J. Biol. Chem. 272(15), 9621-9624 (1997).
107. Ensser A, Fleckenstein B: T-cell transformation and oncogenesis by γ2-herpesviruses Adv. Cancer Res. 93, 91-128 (2005).
108. Grossmann C, Podgrabinska S, Skobe M, Ganem D: Activation of NF-κB by the latent vFLIP gene of Kaposi's sarcoma-associated herpesvirus is required for the spindle shape of virus-infected endothelial cells and contributes to their proinflammatory phenotype. J. Virol. 80(14), 7179-7185 (2006).
109. Bagneris C, Ageichik AV, Cronin N et al.: Crystal structure of a vFlip-IKKγ complex: insights into viral activation of the IKK signalosome. Mol. Cell 30(5), 620-631 (2008).
110. Matta H, Mazzacurati L, Schamus S, Yang T, Sun Q, Chaudhary PM: KSHV oncoprotein K13 bypasses TRAFs and directly interacts with the IκB kinase complex to selectively activate NF-λB without JNK activation. J. Biol. Chem. 282(34), 24858-24865 (2007).
111. Sakakibara S, Pise-Masison CA, Brady JN, Tosato G: Gene regulation and functional alterations induced by Kaposi's sarcoma-associated herpesvirus-encoded ORFK13/vFLIP in endothelial cells. J. Virol. 83(5), 2140-2153 (2009).
112. Fukumura D, Xavier R, Sugiura T et al.: Tumor induction of VEGF promoter activity in stromal cells. Cell 94(6), 715-725 (1998).
113. Tang N, Wang L, Esko J et al.: Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumotigenesis. Cancer Cell 6(5), 485-495 (2004).
114. An FQ, Folarin HM, Compitello N et al.: Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J. Virol. 80(10), 4833-4846 (2006).
115. Mutlu AD, Cavallin LE, Vincent L et al.: In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma. Cancer Cell 11(3), 245-258 (2007).
116. Aoki Y, Jaffe ES, Chang Y et al.: Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 93(12), 4034-4043 (1990).
117. Wang L, Wakisaka N, Tomlinson CC et al.: The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. Cancer Res. 64(8), 2774-2781 (2004).
118. Prakash O, Tang ZY, Peng X et al.: Tumorigenesis and aberrant signaling in transgenic mice expressing the human. herpesvirus-8 K1 gene. J. Natl Cancer Inst. 94(12), 926-935 (2002).
119. Tsai YH, Wu MF, Wu YH et al.: The M type K15 protein of Kaposi's sarcoma-associated herpesvirus regulates microRNA expression via its SH2-binding motif to induce cell migration and invasion. J. Virol. 83(2), 622-632 (2009).
120. Boshoff C., Endo Y, Collins PD et al.: Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 278 (5336), 290-294 (1997).
121. Shin YC, Jon CH, Gack MU, Lee HR, Jung JU: Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 3 stabilizes hypoxia-inducible factor-1 α to induce vascular endothelial growth factor expression. Cancer Res. 68(6), 1751-1759 (2008).
122. Yang TY, Chen SC, Leach MW et al.: Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J. Exp. Med. 191(3), 445-454 (2000).
123. Katano H, Sato Y, Kurata T, Mori S, Sata T: Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology 269(2), 335-344 (2000).
124. Rivas C, Thlick AE, Parravicini C, Moore PS, Chang Y: Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J. Virol. 75(1), 429-438 (2001).
125. Chiou CJ, Poole LJ, Kim PS et al.: Patterns of gene expression and a transactivation function exhibited by the vGCR(ORF74) chemokine receptor protein of Kaposi'a sarcoma-associated herpesvirus. J. Virol. 76(7), 3421-3439 (2002).
126. Bais C, Santomasso B, Coso O et al.: G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391(6662), 86-89 (1998).
127. Montaner S, Sodhi A, Molinolo A et al.: Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 3(1), 33-36 (2003).
128. Radkov SA, Kellam P, Boshoff C: The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat. Med. 6(10), 1121-1127 (2000).
129. Sugaya M, Watanabe T, Yang A et al.: Lymphatic dysfunction in transgenic mice expressing KSHV k-cyclin under the control of the VEGFR-3 promoter. Blood 105(6), 2356-2363 (2005).
130. Brown LF, Yeo KT, Berse B et al.: Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J. Exp. Med. 176(5), 1375-1379 (1992).
131. Olsor TA, Mohanraj D, Carson LF, Ramakrishnan S: Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res. 54(1), 276-280 (1994).
132. Hino R, Uozaki H, Inoue Y et al.: Survival advantage of EBV-associated gastric carcinoma: survivin up-regulation by viral latent membrane protein 2A. Cancer Res. 68(5), 1427-1435 (2008).
133. Stewart S, Dawson CW, Takada K et al.: Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-κB transcription factor pathway. Proc. Natl Acad. Sci. USA 101(44), 15730-15735 (2004).
134. Tierney R, Nagra J, Hutchings I et al.: Epstein-Barr virus exploits BSAP/Pax5 to achieve the B-cell specificity of its growth-transforming program. J. Virol. 81(18), 10092-10100 (2007).
135. Hong YK, Foreman K, Shin JW et al.: Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat. Genet. 36(7), 683-685 (2004).
136. Wang HW, Trotter MW. Lagos D et al.: Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene express on in Kaposi sarcoma. Nat Genet. 36(7), 687-693 (2004).
137. Dupin N, Fisher C, Kellam P et al.: Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc. Natl Acad. Sci. USA 96(8), 4546-4551 (1999).
138. Browning PJ, Sechler JM, Kaplan M et al.: Identification and culture of Kaposi's sarcoma-like spindle cells from the peripheral blood of human immunodeficiency virus-1-infected individuals and normal controls. Blood 84(8), 2711-2720 (1994).
139. Lancrin C, Sroczynska P, Stephenson C, Allen T, Kouskoff V, Lacaud G: The haemangioblast generates haematopoietic cells through a haemogenic endothelium stage. Nature 457(7231), 892-895 (2009).
140. Jiang Y, Jahagirdar BN, Reinhardt RL et al.: Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418(6893), 41-49 (2002).
141. Kalluri R, Zeisberg M: Tibroblasts in cancer. Nat. Rev. Cancer 6(5), 392-401 (2006).